Literature DB >> 24075276

Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer.

Suguru Yamada1, Bryan C Fuchs, Tsutomu Fujii, Yoshie Shimoyama, Hiroyuki Sugimoto, Shuji Nomoto, Shin Takeda, Kenneth K Tanabe, Yasuhiro Kodera, Akimasa Nakao.   

Abstract

BACKGROUND: Pancreatic cancer has a dismal prognosis that is attributed to common local invasiveness and metastasis. Epithelial-to-mesenchymal transition (EMT) plays an important role in cancer invasion and metastasis and is associated with early dissemination. The aim of this study was to evaluate the association between EMT and the prognoses for patients with pancreatic cancer.
METHODS: Immunohistochemistry of E-cadherin and vimentin was performed on surgical specimens from 174 patients who underwent resection of their pancreatic cancers. Tumoral stainings of E-cadherin and vimentin were graded, and EMT statuses were determined by calculating the ratio of vimentin to E-cadherin, whereby patients were categorized into 3 groups: epithelial, intermediate, and mesenchymal. The correlations between EMT statuses and clinicopathologic factors and prognoses were analyzed.
RESULTS: There was a significant correlation between EMT status and CA19-9 levels (P = .020); peritoneal washing cytology (P = .025); portal vein invasion (P = .038); and lymph node metastasis (P = .030). The median survival for patients with epithelial tumors was 40.2 months as compared to 13.7 months for patients with mesenchymal tumors. Multivariate analysis demonstrated that perineural invasion (P = .024); lymph node metastasis (P = .033); and EMT status (P < .0001) were significant prognostic factors. It is interesting that adjuvant chemotherapy (gemcitabine and/or S-1) improved the median survival time from 10.8 to 16.1 months in patients with mesenchymal tumors (P = .002); however, no significant difference was seen in patients with epithelial tumors.
CONCLUSION: EMT status is an important prognostic factor for pancreatic cancer and is associated with portal vein invasion and lymph node metastasis.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24075276     DOI: 10.1016/j.surg.2013.05.004

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  53 in total

1.  High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients.

Authors:  Chao Zhao; Xuefei Li; Chunxia Su; Jiayu Li; Ningning Cheng; Shengxiang Ren; Xiaoxia Chen; Caicun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Upregulation of H19 promotes invasion and induces epithelial-to-mesenchymal transition in esophageal cancer.

Authors:  Cheng Huang; Lihua Cao; Limin Qiu; Xiaoli Dai; Linwei Ma; Yingting Zhou; Huifen Li; Min Gao; Weiyong Li; Qing Zhang; Koulan Han; Hongzhen Lv
Journal:  Oncol Lett       Date:  2015-04-29       Impact factor: 2.967

3.  E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.

Authors:  Alexander P Stark; Hui-Hua Chang; Xiaoman Jung; Aune Moro; Kathleen Hertzer; Mu Xu; Andrea Schmidt; O Joe Hines; Guido Eibl
Journal:  Surgery       Date:  2015-08-18       Impact factor: 3.982

4.  The SDF-1/CXCR4 axis induces epithelial–mesenchymal transition in hepatocellular carcinoma.

Authors:  Xuqi Li; Pei Li; Yuanhong Chang; Qinhong Xu; Zheng Wu; Qingyong Ma; Zheng Wang
Journal:  Mol Cell Biochem       Date:  2014-07       Impact factor: 3.396

Review 5.  Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies.

Authors:  Agnieszka Anna Rucki; Lei Zheng
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

6.  Epithelial-to-mesenchymal transition in human esophageal cancer associates with tumor progression and patient's survival.

Authors:  Jian Liu; Lujun Chen; Haifeng Deng; Bin Xu; Min Li; Xiao Zheng; Changping Wu; Jingting Jiang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 7.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

8.  Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma.

Authors:  Cheng-Hao Wang; Xiao-Dong Zhu; De-Ning Ma; Hui-Chuan Sun; Dong-Mei Gao; Ning Zhang; Cheng-Dong Qin; Yuan-Yuan Zhang; Bo-Gen Ye; Hao Cai; Wen-Kai Shi; Man-Qin Cao; Zhao-You Tang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

9.  A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.

Authors:  Andrew H Ko; Tanios Bekaii-Saab; Jessica Van Ziffle; Olga M Mirzoeva; Nancy M Joseph; AmirAli Talasaz; Peter Kuhn; Margaret A Tempero; Eric A Collisson; R Kate Kelley; Alan P Venook; Elizabeth Dito; Anna Ong; Sharvina Ziyeh; Ryan Courtin; Regina Linetskaya; Sanaa Tahiri; W Michael Korn
Journal:  Clin Cancer Res       Date:  2015-08-06       Impact factor: 12.531

10.  Periductal stromal collagen topology of pancreatic ductal adenocarcinoma differs from that of normal and chronic pancreatitis.

Authors:  Cole R Drifka; Jo Tod; Agnes G Loeffler; Yuming Liu; Gareth J Thomas; Kevin W Eliceiri; W John Kao
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.